Il trattamento con farmaci intravitreali anti-VEGF in pazienti naïve in Italia:

Global & Regional Health Technology Assessment

MAlbrecht¹ 

关键词: Aflibercept;    Intravitreal anti-VEGF treatment;    Ranibizumab;    Vascular-endothelial-growth-factor;   

DOI  :  10.1177/2284240318793905

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Background:Ranibizumab and aflibercept are approved in Italy for the anti-VEGF (vascular-endothelial-growth-factor) treatment of four retinal diseases: neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and retinal vein occlusion (RVO). The objective was to gather information about their utilization in a real-world setting of an Italian hospital.Methods:A retrospective study was conducted at San Raffaele Hospital on 2,117 naïve patients who started treatment in 2013-2015.Results:The mean age of patients was 70 years. The larger groups of patients were those affected by AMD (60.5%) and DME (23.4%). Almost 40% of DME patients were treated in both eyes. On average, AMD patients received 3.97 injections/patient/year; DME: 4.22; mCNV: 2.01; RVO: 3.15. Among treated eyes, 75% received no more than 4 injections/year. One eye out of five was treated only once a year. A trend was highlighted in AMD and DME: the frequency of administrations ...

【 授权许可】

CC BY